1 于浩,蒋虹,佟巍.猴副流感病毒SV5 PCR检测方法的建立与初步应用[J].中国实验动物学报,2006,14(1):32~35. 2 刘晓乐,张敏敏,陈焕春.牛副流感病毒3型RT-PCR检测方法的建立[J].中国奶牛,2011,22:1~4. 3 孙贺廷,夏咸柱,高玉伟.虎血清中犬副流感病毒的抗体流行病学调查研究[J].畜牧与兽医,2004,36(9):4~5. 4 师新川,温永俊,王凤雪,等. 牛副流感病毒3型RT-LAMP检测方法的建立及应用[J].中国畜牧兽医,2012,39(11):31~34. 5 杨敬.犬副流感病毒[J].中国动物检疫,1996,13(1):35~37. 6 陆承平.兽医微生物学[M].第3版.北京:中国农业出版社,2007. 7 Bukreyev A, Marzi A, Feldmann F, et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge[J]. Virology, 2009,383:348~361. 8 Ellis J. Bovine parainfluenza-3 virus[J].The Veterinary Clinics of North America Food Animal Practice, 2010,26:575~593. 9 Greenberg D P, Walker R E, Lee M S, et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy[J]. J Infect Dis, 2005,191:1116~1122. 10 Jones B, Zhan X, Mishin V, et al. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV[J]. Vaccine, 2009, 27:1848~1857. 11 Karron R A, Thumar B, Schappell E, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children[J]. Vaccine, 2012, 30:3975~3981. 12 Madhi S A, Cutland C, Zhu Y, et al.Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers[J]. Vaccine, 2006, 24:2432~2439. 13 Nishio M, Tsurudome M, Garcin D, et al. Human parainfluenza virus type 2 L protein regions required for interaction with other viral proteins and mRNA capping[J]. J Virol,2011, 85:725~732. 14 Roth J P, Li J K, Smee D F. A recombinant, infectious human parainfluenza virus type 3 expressing the enhanced green fluorescent protein for use in high-throughput antiviral assays[J]. Antiviral Research,2009,82:12~21. 15 Roth J P, Li J K,Barnard D L. Human parainfluenza virus type 3 (HPIV-3): Construction and rescue of an infectious, recombinant virus expressing the enhanced green fluorescent protein (EGFP)[J]. Curr Protoc Microbiol Chapter,2010,15: 11~15. 16 Sato M,Wright P F.Current status of vaccines for parainfluenza virus infections[J]. the Pediatric Infectious Disease Journal, 2008,27: 123~125. 17 Schaap-Nutt A, Higgins C, Amaro-Carambot E, et al. Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates[J]. Journal of Virology, 2011, 85:4007~4019. 18 Skiadopoulos M H, Surman S, Tatem J M, et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine[J]. Journal of Virology,1999, 73:1374~1381. 19 Skiadopoulos M H, Tatem J M, Surman S R, et al. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys[J]. Vaccine,2002, 20:1846~1852. 20 Skiadopoulos M H, Schmidt A C, Riggs J M, et al. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic[J]. Journal of Virology,2003, 77:1141~1148. 21 Tao T, Skiadopoulos M H, Davoodi F, et al. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates[J]. Journal of Virology, 2000,74:6448~6458. 22 Terrier O, Cartet G, Ferraris O, et al. Characterization of naturally occurring parainfluenza virus type 2 (hPIV-2) variants[J]. Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology,2008,43:86~92. 23 Vangeel I, Ioannou F, Riegler L, et al. Efficacy of an intranasal modified live bovine respiratory syncytial virus and temperature-sensitive parainfluenza type 3 virus vaccine in 3-week-old calves experimentally challenged with PI3V[J]. Vet J,2009, 179:101~108. 24 Zhang L, Limberis M P, Thompson C, et al. Alpha-fetoprotein gene delivery to the nasal epithelium of nonhuman primates by human parainfluenza viral vectors[J]. Human Gene Therapy, 2010,21:1657~1664. 25 Zhan X, Slobod K S, Krishnamurthy S, et al. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections[J]. Vaccine,2008, 26:3480~3488. |